0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Atripla - API Insight,2019
Published Date: February 2019
|
Report Code: DELV-Drug-22
Home | Market Reports
Atripla API Insight 2019

Atripla - API Insight,2019

Code: DELV-Drug-22
Report
February 2019
Pages:30
Delveinsight
Description
Table of Content
Tables & Figures

Introduction
DelveInsight's, “Atripla - API Insight, 2019” report provides product and API manufacturers’ details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Atripla . The report also highlights the patent details of Atripla .

Methodology
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the report

• A comprehensive product overview including product description, regulatory milestones, safety, pharmacological properties, clinical trials, and product development activities have been elaborated in this report
• Patent information around Atripla in United States (US) and Europe (EU) has been highlighted
• API manufacturers for Atripla in United States, Europe, China and India
• The report contains historical and forecasted sales for Atripla till 2021
• Enlists the market competition and emerging therapies in the space where Atripla operates

Reasons to Buy
• Evaluate the marketing status of Atripla to exploit opportunities for generic Atripla development opportunities
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details with respect to Atripla
• API intelligence over Atripla and gaining primary intelligence over Active Ingredient manufacturers by country
• Make more informed business decisions from insightful and in-depth analysis of the Atripla 's performance

1. Atripla Overview
2. Atripla Global Sales Assessment
• Atripla Historical Global Sales
• Atripla Forecasted Global Sales
3. Product Description
• Mechanism of Action
• Pharmacodynamic Properties
• Pharmacokinetic Properties
4. Product Details by country
5. Patent Information
6. Global API Manufacturers Assessment
• Active Pharmaceutical Ingredient (API) Manufacturers by Country
• Active Pharmaceutical Ingredient (API) Manufacturers by Region
Appendix
Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Atripla Historical Global Sales till 2018 (in million USD)
Table 2: Atripla Forecasted Global Sales from 2019-2021 (in million USD)
Table 3: Atripla General Description
Table 4: Product Details by country
Table 5: Patent Information
Table 6: API Manufacturers by country
Table 7: API Manufacturers by Region

List of Figures

Figure 1: Atripla Historical Global Sales till 2018 (in million USD)
Figure 2: Atripla Forecasted Global Sales from 2019-2021 (in million USD)
Figure 3: Atripla Patent Details
Figure 4: API Manufacturers by Country
Figure 5: API Manufacturers by Region

SELECT A FORMAT
Added to Cart
Electronic (PDF)

$500

This license allows only one user to access the PDF.
Electronic (PDF)

$1000

This license allows all the users of an enterprise residing in one location to access the PDF
Electronic (PDF)

$1500

This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Leap India
SIMILAR REPORTS